GlassScriptPhysician profile
John Freeland Jayroe
NPI 1801246129
$9,385.45
in general payments reported to CMS, 2019-2025
45 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $1,441 · 2021: $1,939 · 2022: $1,746 · 2023: $1,536 · 2024: $1,214 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,770.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,081.86 | 2021-2025 | |
| Amgen INC. | $1,044.80 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $985.37 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $978.70 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $881.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $551.70 | 2019-2025 | |
| Astellas Pharma US INC | $401.29 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $398.15 | 2020-2021 | |
| Novo Nordisk INC | $350.81 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $231.58 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Biohaven Pharmaceuticals, INC. | $227.42 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $204.84 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.27 | 2019-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.11 | 2020-2024 | Xifaxan, Trulance |
| Corium, LLC | $159.96 | 2022-2023 | Azstarys |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jayroe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.